As recently published in Biomacromolecules, researchers CQM at Universidade de Madeira report their evaluation of generation 4 and 5 bis-MPA dendrimers as drug delivery vehicles for anti-cancer drug doxorubicin (DOX), as well as the cytotoxicity of the dendrimers toward healthy human cell lines.
